1-3 of 3
Raymond Taetle
Close
Sort by
Journal Articles

Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma

Clinical Trials & Observations
Nicholas Di Bella, Raymond Taetle, Kathryn Kolibaba, Thomas Boyd, Robert Raju, David Barrera, Ernest W. Cochran, Jr, Philip Y. Dien, Roger Lyons, Peter J. Schlegel, Svetislava J. Vukelja, Julie Boston, Kristi A. Boehm, Yunfei Wang, Lina Asmar
Journal: Blood
Blood (2010) 115 (3): 475–480.
https://doi.org/10.1182/blood-2009-08-233155
Published: 2010
Journal Articles

Results of a Phase II Study of Bortezomib in Patients with Relapsed or Refractory Indolent Lymphoma.

Nicholas Di Bella, MD, Raymond Taetle, MD, Kathryn S. Kolibaba, MD, Thomas E Boyd, MD, Robert N Raju, MD, David N Barrera, DO, Ernest Cochran, MD, Philip Dien, MD, David Hakimian, MD, Roger M. Lyons, MD, Peter J Schlegel, MD, Svetislava J Vukelja, MD, Julie Boston, RN, Kristi A Boehm, MS, Yunfei Wang, MS, Lina Asmar, PhD
Journal: Blood
Blood (2008) 112 (11): 1572.
https://doi.org/10.1182/blood.V112.11.1572.1572
Published: 2008
Journal Articles

Stimulation of Hematopoiesis by Amifostine in Patients With Myelodysplastic Syndrome

Alan F. List, Farah Brasfield, Ruth Heaton, Betty Glinsmann-Gibson, Linda Crook, Raymond Taetle, Robert Capizzi
Journal: Blood
Blood (1997) 90 (9): 3364–3369.
https://doi.org/10.1182/blood.V90.9.3364
Published: 1997